Neuraxis, INCNRXS
Price (close)
$7.75
Market cap
$97.3M
P/E
—
Revenue (TTM)
$5.3M
Net income
-$7.7M
Dividend yield
—
1-year total return
181.8%
Net margin
-144.4%
Revenue growth
65.2%
Debt / equity
0.01x
What Neuraxis, INC does.
technology company focused on neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system,
specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. With several indications in the market and
additional clinical trials of Percutaneous Electrical Nerve Field Stimulation (PENFS) in multiple pediatric and adult conditions underway,
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $2.7M | $2.5M | $2.7M | $3.6M |
| Net income | — | -$4.8M | -$14.6M | -$8.2M | -$7.8M |
| Free cash flow | — | -$2.3M | -$6.7M | -$6.1M | -$6.5M |
More on NRXS.
- Neuraxis, INC summary
- Neuraxis, INC financial statements
- Neuraxis, INC key metrics
- Neuraxis, INC health scores and style box
- Neuraxis, INC earnings
- Neuraxis, INC dividends
- Neuraxis, INC valuation
- Neuraxis, INC ownership and insiders
- Neuraxis, INC peers
Figures from Neuraxis, INC's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.